Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2835-2841

  Chao, Angel ^a   Hsu, Kuang Hung ^b   Lai, Chyong Huey ^a,d   Huang, Huei Jean ^a   Hsueh, Swei ^a   Lin, Sheue Rong ^c   Jung, Shih Ming ^a   Chao, Fang Yu ^a   Huang, Shang Lang ^a   Huang, Chu Chun ^a   Yang, Jung Erh ^a   Chang, Ting Chang ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c Public Health Bureau Taoyuan County Government   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical cancer screening; Human papillomavirus; Pap smear; Polymerase chain reaction (PCR); Prevalence

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CORRELATION ANALYSIS; DNA DETERMINATION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HUMAN PAPILLOMAVIRUS 58; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; INFORMED CONSENT; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PAPANICOLAOU TEST; POPULATION RESEARCH; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TAIWAN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 43049092273     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23441     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Department of Health, Executive Yuan, Health Statistics in Taiwan, 2005. http://www.doh.gov.tw/EN2006/DM/DM2_p01.aspx?class_no=390&now_fod_list_no= 9291&level_no=3&doc_no=52235.
3. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-19.
4. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32:S43-S51.
5. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-95.
6. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-6.
7. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
8. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
9. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:1246-56.
10. Perry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7.
11. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005;105:905-18.
12. Quint WG, Pagliusi SR, Lelie N, de Villiers EM, Wheeler CM. Results of the first world health organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006;44:571-9.
13. Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, Lin CY, Yan CC, Chou HH, Huang KG, Huang HJ, Wu TI, et al. Comparison between the hybrid capture II test and a SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006;44:1733-9.
14. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, Chao FY, Qiu JT, Hong JH, Chou HH, Chang TC, Chang CJ. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007;120:1999-2006.
15. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, Lin CT, Huang SL, Hong JH, Chou HH, Wu TI, Huang KG, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 2007;25:3628-34.
16. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
17. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006;24:S23-S28.
18. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
19. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr, Young N. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-19.
20. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006;101:40-5.
21. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
22. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-74.
23. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
24. Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S. Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study. Br J Cancer 2006;95:1593-7.
25. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-19.
26. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
27. Green J, Berrington de Gonzalez A, Smith JS, Franceschi S, Appleby P, Plummer M, Beral V. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003;88:1713-20.
28. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148-53.
29. Smith EM, Ritchie JM, Levy BT, Zhang W, Wang D, Haugen TH, Turek LP. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev 2003;27:472-80.
30. Petignat P, Faltin D, Goffin F, Billieux MH, Stucki D, Sporri S, Vassilakos P. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. Cancer 2005;105:126-32.
31. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev 2007;16:288-94.